Dr. Oh Discusses Choosing Abiraterone in Prostate Cancer

William K. Oh, MD
Published: Thursday, Dec 14, 2017



William K. Oh, MD, chief, Division of Hematology and Medical Oncology, professor of medicine and urology, Mount Sinai School of Medicine, explains when he would choose abiraterone acetate (Zytiga) for patients with prostate cancer.

Abiraterone acetate has become a major player in the prostate cancer treatment landscape, as noted in a plenary session during the 2017 ASCO Annual Meeting.

Oh says that it is ultimately up to the patient, but price is a consideration, as it is an expensive therapeutic option.
 
SELECTED
LANGUAGE


William K. Oh, MD, chief, Division of Hematology and Medical Oncology, professor of medicine and urology, Mount Sinai School of Medicine, explains when he would choose abiraterone acetate (Zytiga) for patients with prostate cancer.

Abiraterone acetate has become a major player in the prostate cancer treatment landscape, as noted in a plenary session during the 2017 ASCO Annual Meeting.

Oh says that it is ultimately up to the patient, but price is a consideration, as it is an expensive therapeutic option.
 



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Oncology Briefings™: Current Perspectives on Preventing and Managing Tumor Lysis SyndromeJun 30, 20191.0
Community Practice Connections™: 2nd Annual International Congress on Oncology Pathology™Aug 31, 20191.5
Publication Bottom Border
Border Publication
x